日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

克唑替尼治疗MET扩增或14号外显子缺失的肿瘤患者:NCI-MATCH ECOG-ACRIN试验(EAY131)C1和C2子方案的结果

Coleman, Niamh; Wei, Zihan; Iafrate, A John; Zwiebel, James A; Sharon, Elad; Gray, Robert J; Wang, Victoria; McShane, Lisa M; Rubinstein, Larry V; Patton, David R; Williams, P Mickey; Hamilton, Stanley R; Takebe, Naoko; Williams, Travis; Croley, Jessica J; Onitilo, Adedayo A; Tricoli, James V; Cheng, Ju; Karlovich, Chris; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay; O'Dwyer, Peter J; Hong, David S; Chen, Alice P; Flaherty, Keith T

Oncogene-driven lung cancer in the era of radiogenomics: current evidence and future developments

放射基因组学时代癌基因驱动的肺癌:现有证据与未来发展

Ryan, James; Kavanagh, John; Coleman, Niamh

Challenges and opportunities in the immunotherapy era: balancing expectations with hope in small-cell lung cancer

免疫疗法时代的挑战与机遇:在小细胞肺癌治疗中平衡期望与希望

Khan, Raza; Coleman, Niamh

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

mTORC1/2抑制剂Sapanisertib(CB-228/TAK-228)联合二甲双胍治疗mTOR/AKT/PI3K通路改变和晚期实体恶性肿瘤患者的I期研究

Subbiah, Vivek; Coleman, Niamh; Piha-Paul, Sarina A; Tsimberidou, Apostolia M; Janku, Filip; Rodon, Jordi; Pant, Shubham; Dumbrava, Ecaterina E Ileana; Fu, Siqing; Hong, David S; Zhang, Shizhen; Sun, Ming; Jiang, Yunfang; Roszik, Jason; Song, Juhee; Yuan, Ying; Meric-Bernstam, Funda; Naing, Aung

Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.

sapanisertib (CB-228/TAK-228/MLN0128) 与 ziv-aflibercept 联合治疗晚期实体瘤患者的 I 期研究

Coleman Niamh, Stephen Bettzy, Fu Siqing, Karp Daniel, Subbiah Vivek, Ahnert Jordi Rodon, Piha-Paul Sarina A, Wright John, Fessahaye Senait N, Ouyang Fengying, Yilmaz Bulent, Meric-Bernstam Funda, Naing Aung

Antibody-drug conjugates in lung cancer: dawn of a new era?

抗体药物偶联物在肺癌治疗中的应用:新时代的曙光?

Coleman, Niamh; Yap, Timothy A; Heymach, John V; Meric-Bernstam, Funda; Le, Xiuning

HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma

HRAS突变定义了头颈部鳞状细胞癌的一个独特亚组

Coleman, Niamh; Marcelo, Kathrina L; Hopkins, Julia F; Khan, Nusrat Israr; Du, Robyn; Hong, Lingzhi; Park, Edward; Balsara, Binaifer; Leoni, Mollie; Pickering, Curtis; Myers, Jeffrey; Heymach, John; Albacker, Lee A; Hong, David; Gillison, Maura; Le, Xiuning

Worth the paper they are printed on? Findings from an independent evaluation of the understandability of patient information leaflets for antiseizure medications

这些说明书真的值那么多纸吗?一项针对抗癫痫药物患者信息手册易懂性的独立评估结果

Noble, Adam J; Haddad, Sara; Coleman, Niamh; Marson, Anthony G

The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response

Schlafen 11 (SLFN11) 作为靶向 DNA 损伤反应的预测性生物标志物的作用

Coleman, Niamh; Zhang, Bingnan; Byers, Lauren A; Yap, Timothy A

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping

非小细胞肺癌中MET外显子14跳跃突变伴随的基因组改变的分布格局和克隆优势

Le, Xiuning; Hong, Lingzhi; Hensel, Chuck; Chen, Rongrong; Kemp, Haley; Coleman, Niamh; Ciunci, Christine A; Liu, Stephen V; Negrao, Marcelo V; Yen, Jennifer; Xia, Xuefeng; Scheuenpflug, Juergen; Stroh, Christopher; Juraeva, Dilafruz; Tsao, Anne; Hong, David; Raymond, Victoria; Paik, Paul; Zhang, Jianjun; Heymach, John V